LOS ANGELES, CA--(MARKET WIRE)--Jan 22, 2009 -- Cardo Medical (OTC BB:CDOM.OB - News), a company engaged in the development of orthopedic medical devices, announces the initial release of its Press-Fit Total Hip system. The Press-Fit Total Hip system incorporates a dual taper design which has a long, proven clinical history with great implant success rates. Cardo Medical’s innovations will include instrument enhancements which are designed to significantly improve upon existing offerings. The Press-Fit Total Hip system has already completed a number of successful surgeries with great feedback from surgeon thought leaders on the implant design and instrument innovations. The initial regional release will follow with a rolling commercial release to an expanded surgeon network over the first half of this year. As a complement to the Press-Fit Total Hip system, Cardo Medical is also preparing to release its Bipolar Hip system within the next month.
Dr. Andrew Brooks, Chairman and Chief Executive Officer of Cardo Medical, stated, “Cardo Medical is proud to announce our first hip implant system release. In addition to the proven design incorporated into our Press-Fit Total Hip system, we will be rapidly expanding our hip offering to also include a Bipolar Hip and novel surgical techniques for minimally invasive total hip surgery. Cardo Medical has a robust pipeline of product and technology innovations we plan to release this year, and look forward to strong market acceptance and appeal. We expect to make significant impact on the state of the art of total hip surgery.”
About Cardo Medical, Inc.
Cardo Medical (OTC BB:CDOM.OB - News) develops reconstructive orthopedic and spinal surgery products through advanced engineering and focuses on product development, marketing and distribution within the US market. Cardo Medical’s superior engineering talent closely collaborates with leading surgeons around the country to create products that reduce or eliminate joint pain and allow patients to achieve more active lives. The company’s cutting edge products are specifically developed with patients, surgeons and OR staff in mind and are designed to reduce operative time, enhance surgical technique, shorten hospital stays, reduce recovery time and improve outcomes. Cardo Medical’s product portfolio includes devices for knee, hip, spinal fusion and motion preservation arthroplasty and replacement, many of which have already received FDA clearance. Cardo Medical has a robust and innovative product pipeline pending both USPTO and FDA submission and clearance.
Cardo Medical works in small, focused development teams in concert with physicians to rapidly develop products from concept to launch. We are committed to exceeding the standards by which any device company is judged. Please visit our website at www.cardomedical.com for more information on the Align 360 Total Knee System in addition to our portfolio of other Reconstructive and Spinal Implant systems.
This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), regarding product development efforts and other non-historical facts about expectations, beliefs or intentions regarding the business, technologies and products, financial condition, strategies or prospects. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, including the risks that any products under development may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the ailments being studied or for other ailments. In addition, forward-looking statements also may be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. We do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
Contact:
CONTACT: Cardo Medical, Inc. Andrew A. Brooks, M.D. CEO (310) 274-2036
Source: Cardo Medical
